Statement of Principles concerning allergic contact dermatitis (Reasonable Hypothesis) (No. 1 of 2021)

The central concept is “allergic contact dermatitis” as defined in subsection 7(2). It means inflammation of an area of skin from exposure to an allergen that has been applied to the same area, being a cell-mediated delayed-type hypersensitivity reaction from a substance to which the individual has previously been sensitised. The definition expressly excludes atopic dermatitis (eczema), irritant contact dermatitis, local skin hypersensitivity from metal implants, photocontact dermatitis, systemic allergic dermatitis, and urticaria. This exclusion is critical: a claimant with dermatitis that fits one of those excluded types cannot rely on this SoP. The instrument also covers death from allergic contact dermatitis, meaning death from a terminal event (pneumonia, respiratory failure, cardiac arrest, circulatory failure, cessation of brain function) contributed to by allergic contact dermatitis. The concept of “allergen” is defined in Schedule 1 as a substance capable of producing an immune response and inflammation in the skin, with a non-exhaustive list including chromium, nickel, fragrances, rubber accelerators, formaldehyde, and many others. The definition is broad but bounded by the requirement of being “applied to the same area of skin” for the hypersensitivity reaction.

“Relevant service” is defined by reference to six categories: operational service, peacekeeping service, hazardous service, and British nuclear test defence service under the VEA; and warlike service and non-warlike service under the MRCA. This restricts the instrument to those with qualifying service; ordinary peacetime service may not be covered.

“Reasonable hypothesis” is the standard of proof used under section 120A VEA for operational service claims. The instrument does not define this phrase but provides the factors that must “as a minimum” exist before a reasonable hypothesis can be said to be raised. The factors themselves are the core of the instrument. Factor 9(1) requires the affected area of skin to have been exposed to an allergen within the two weeks before the clinical onset of allergic contact dermatitis. Factor 9(1A) introduces a two-stage process: a sensitising exposure to an allergen before clinical onset, where the sensitising exposure is defined as an exposure without symptoms, and the clinical onset occurs within two weeks of a subsequent exposure to the same allergen. The note clarifies that the initial sensitising exposure may be systemic or cutaneous and may have occurred months to years earlier. Factor 9(2) mirrors factor 9(1) but applies to clinical worsening rather than onset. Factor 9(3) is the catch-all: inability to obtain appropriate clinical management. This factor does not require a temporal window but requires the decision-maker to find that the claimant could not obtain appropriate treatment and that this inability contributed to the condition. The instrument also provides for cross-sensitisation between allergens, meaning that exposure to one allergen may cause reaction to another chemically similar substance.

The direct subjects are veterans and members of the Defence Force who have rendered relevant service as defined. Specifically, persons who have rendered operational service, peacekeeping service, hazardous service, or British nuclear test defence service under the VEA, and persons who have rendered warlike or non-warlike service under the MRCA. The instrument also applies to members of Peacekeeping Forces and Forces as defined in the VEA. It affects their dependents indirectly, because death claims can arise from allergic contact dermatitis contributed to by service factors. The instrument also binds the Repatriation Medical Authority, which is required under section 196B of the VEA to determine Statements of Principles based on sound medical-scientific evidence. The Authority declares in section 8 that it is of the view that such evidence exists for allergic contact dermatitis. The instrument is binding on primary decision-makers in the Department of Veterans’ Affairs and the Military Rehabilitation and Compensation Commission when they assess claims. It also affects legal practitioners and advocates who must frame claims to meet the factors, and medical professionals providing reports on causation. The instrument indirectly affects the Commonwealth budget because it influences the rate at which claims succeed, thus affecting compensation payouts for medical expenses, incapacity payments, and permanent impairment. The instrument does not directly affect private enterprises, but the list of allergens includes many industrial and commercial substances: chromium in cement, nickel in buttons, rubber accelerators in gloves, formaldehyde in disinfectants, and fragrances in personal care products. This means that claimants must identify a specific allergen exposure linked to service, which often involves tracing exposure to military equipment, uniforms, workplace chemicals, or medical products used during service. The practical burden falls on both the claimant to provide evidence of exposure and on the Commonwealth to assess whether that exposure meets the factor’s requirements. The instrument does not apply to civilian workers or to veterans whose service is not relevant.

The instrument does not impose duties in the usual sense of a regulatory statute. Its key effect is to establish a right in a claimant to have their claim assessed using these factors. More precisely, the instrument specifies that at least one factor from section 9 “must as a minimum exist before it can be said that a reasonable hypothesis has been raised.” This creates a legal requirement on decision-makers: they cannot find a reasonable hypothesis if none of the factors is present with respect to relevant service. Conversely, if a factor is satisfied and the evidence supports a reasonable hypothesis, the claim must be accepted under the reverse onus provision of section 120A(3) of the VEA, unless there is a contrary finding disproving the hypothesis beyond reasonable doubt. The duty of the Repatriation Medical Authority is to determine these instruments based on sound medical-scientific evidence, but that duty is to the Parliament, not directly to claimants. Claimants have a right to have their claims determined in accordance with the instrument as in force at the time of decision. There is also a right to argue that even if none of the listed factors are met, other medical evidence may nonetheless raise a reasonable hypothesis. The instrument states “at least one of the following factors must as a minimum exist” - this is a floor, not a ceiling. The instrument does not confer any new enforceable rights beyond the underlying compensation legislation. It does, however, constrain administrative discretion: a decision-maker cannot reject a claim solely because the evidence does not fit a factor if another factor or other evidence would reasonably support the hypothesis. For claimants, the key right is to have the decision-maker consider whether the factor relates to relevant service. Section 10 requires that the existence of any factor must be related to the relevant service rendered. For factors 9(2) and 9(3), additional restrictions apply: they only apply to material contribution to aggravation where the condition was suffered or contracted before or during (but did not arise out of) relevant service. This distinction matters for claims where the dermatitis existed before service. The instrument does not create obligations for private third parties, such as employers or product manufacturers, though they may be relevant in identifying allergen exposure.

The instrument contains no penalty provisions. It is not a penal instrument; it is a rules-based evidentiary instrument for administrative decision-making. Enforcement of the instrument is not a matter of prosecution or fine. Rather, non-compliance by a decision-maker can be challenged through internal review (under the VEA) and then appeal to the Administrative Appeals Tribunal, and subsequently to the Federal Court on questions of law. A decision-maker who misapplies the factors - for example, by requiring proof beyond a reasonable hypothesis stage, or by ignoring the sensitising exposure factor - may have the decision set aside and remitted. The Repatriation Medical Authority itself has no enforcement mechanism; its instruments are legislative instruments that automatically bind decision-makers. There is no provision for sanctions against claimants who make false statements, though general provisions in the VEA and MRCA about fraud would apply. In practice, the enforcement risk is that a claimant’s failure to satisfy a factor will result in denial of the claim. That is not a penalty but an administrative outcome. The instrument also interacts with the “reasonable hypothesis” standard, which shifts the burden to the Commonwealth to disprove the hypothesis once the factors are met. That standard is not punitive but evidential. Because the instrument is a legislative instrument registered under the Legislation Act 2003, it may be disallowed by Parliament if it fails to comply with certain procedures, but that has not occurred here. The amendment history shows only one amendment, with no disallowance. There is no private right of action under this instrument. The costs of compliance are borne by the claimant (gathering evidence, obtaining medical reports) and by the Department (processing claims, possibly commissioning expert opinions). The instrument indirectly penalises claimants who cannot document the precise timing of exposure within the two-week windows, as that failure will likely lead to rejection. This is a practical enforcement of strict temporal limits.

This instrument is made under section 196B(2) of the VEA, which deals with Statements of Principles for the reasonable hypothesis standard. A parallel instrument under section 196B(3) exists for the balance of probabilities standard, used for claims involving hazardous service or certain other categories. This instrument does not reference that counterpart, but decision-makers must apply the correct standard depending on the type of service. The instrument applies to claims under both the VEA and the MRCA by virtue of section 338 of the MRCA, which adopts the Statements of Principles. It interacts with the VEA and MRCA overarching provisions on causation, standard of proof, and onus. Section 120A of the VEA provides that a reasonable hypothesis cannot be raised unless the injury or disease is of a kind determined by the Authority to be related to service. This instrument is that determination for allergic contact dermatitis. It also interacts with other Statements of Principles. Section 11 states that if a factor in section 9 refers to an injury or disease covered by another Statement of Principles, then the factors in that other SoP apply. This means that where a claimant’s allergic contact dermatitis is linked, for example, to a sensitising exposure that itself caused a separate recognised disease, the decision-maker must consult the relevant SoP for that disease. This creates a potential network of cross-references. The instrument also interacts with the common law of causation indirectly; the VEA and MRCA are statutory schemes that displace common law negligence claims for service-related injuries. The instrument also interacts with the Health Insurance Act 1973 and the National Health Act 1953 to the extent that medical treatment for allergic contact dermatitis is covered, but that is not directly the instrument’s domain. The instrument does not affect state workers’ compensation schemes; it is specific to Commonwealth military compensation. It also interacts with the Veterans’ Entitlements Act provisions governing “terminal events”: the definition in Schedule 1 mirrors that used in other SoPs for death claims. There is no express interaction with the Safety, Rehabilitation and Compensation Act 1988 (SRCA) for Defence personnel covered by MRCA, but the MRCA replaced the SRCA for new claims from 2004. The instrument does not interact with criminal law or privacy laws. It is itself a legislative instrument subject to the Legislation Act 2003, meaning it is registered, tabling, and subject to disallowance. The amendment history shows it was amended once, and the instrument includes a note about compilations and misdescribed amendments.

The instrument originated as the Statement of Principles concerning allergic contact dermatitis (Reasonable Hypothesis) (No. 1 of 2021), registered on 6 January 2021 and commencing on 25 January 2021. It was amended by the Amendment Statement of Principles concerning allergic contact dermatitis (Reasonable Hypothesis) (No. 88 of 2022), registered on 26 August 2022 and commencing on 19 September 2022. The amendment made three changes. First, subsection 9(1) (exposure to allergen within two weeks before clinical onset) was substituted. The original version is not reproduced in the compilation, but the substitution likely refined the wording. Second, a new subsection 9(1A) was added: “having a sensitising exposure to an allergen before the clinical onset of allergic contact dermatitis.” This added a second pathway for establishing a causal link, recognising that a person could be sensitised without symptoms and later develop dermatitis upon re-exposure. Third, subsection 9(2) (exposure before clinical worsening) was substituted. The amendment also added the definition of “sensitising exposure to an allergen” in Schedule 1. That definition provides that the sensitising exposure is an exposure without symptoms, and that the clinical onset must occur within two weeks of a subsequent exposure to the same allergen. The note explains that the initial sensitising exposure may be systemic or cutaneous and may have occurred months to years earlier. This amendment broadened the potential claim base, as it allows claims where the claimant cannot pinpoint a single exposure event that caused symptoms, but can show a history of exposure without reaction followed by a later exposure that triggered the dermatitis. The amendment did not change the definition of allergic contact dermatitis, nor the exclusions. It also did not change the term “allergen” or the list of examples. The amendment history in endnote 4 shows that sections 2 and 4 were repealed by operation of the Legislation Act 2003 (sections 48D and 48C respectively), which is a standard housekeeping provision for legislative instruments. No other provisions were amended.

The instrument itself does not include any references to litigation. No cases are cited in the text. This is common for Statements of Principles; they are legislative instruments made by an expert body, not judgments. However, it is well known that Statements of Principles are frequently litigated in the Administrative Appeals Tribunal and the Federal Court. Claimants challenge decisions where a factor is found not to exist, or where the decision-maker misapplied the temporal windows, or where the relationship to service was not established. The definition of allergic contact dermatitis and its exclusions have been the subject of argument, particularly around the line between allergic contact dermatitis and irritant contact dermatitis or atopic dermatitis. The sensitising exposure factor introduced in 2022 may lead to litigation over what constitutes a “sensitising exposure” and whether the two-week window after re-exposure is rigid. The requirement that the exposure must be to the “affected area of skin” may also be contested, especially for airborne allergens where the area may be widespread. The note on cross-sensitisation may generate arguments about whether a particular allergen is sufficiently similar. Because the instrument is based on the Repatriation Medical Authority’s assessment of sound medical-scientific evidence, litigants sometimes challenge the adequacy of the Authority’s reasoning, though such challenges are limited under the judicial review principles. The instrument does not provide any information about past litigation, and no court or tribunal decisions are listed in the endnotes. The absence of any embedded case references is notable, but not unusual. Practitioners should be aware that the Federal Court and the AAT have issued many decisions on Statements of Principles generally, setting out principles of interpretation, such as that the factors are not to be read as exhaustive of all possible causal pathways, and that they set a “minimum” threshold. See, for example, Repatriation Commission v Hancock (2003) 77 ALD 135 (not in source). The instrument itself does not incorporate any such case law.

Several provisions contain traps for the unwary. The most significant is the two-week temporal window in factors 9(1), 9(1A), and 9(2). A claimant who had exposure three weeks before onset cannot rely on these factors unless the condition is clinical worsening (factor 9(2)) and the exposure occurred within two weeks of the worsening. The sensitising exposure factor also requires the eventual re-exposure to be within two weeks of onset, even though the original sensitising exposure could be years earlier. Proving the timing of both exposure and onset may be difficult, especially for delayed-type hypersensitivity reactions that may not appear immediately. Another trap: “allergic contact dermatitis” is narrowly defined. Many common dermatitis presentations are specifically excluded: atopic dermatitis (eczema), irritant contact dermatitis, photocontact dermatitis, and systemic allergic dermatitis. A claimant diagnosed with “contact dermatitis” that could be allergic or irritant must obtain a definitive diagnosis confirming allergic contact dermatitis with patch testing; otherwise the claim may fail. The exclusion for “local skin hypersensitivity associated with metal implants” means that veterans with metal implants such as joint replacements who develop dermatitis over the implant site cannot use this SoP; they would need a different SoP. The definition of “allergen” includes a non-exhaustive list, but the instrument does not require the allergen to be one of the listed examples. However, a claimant who alleges exposure to a rare allergen may struggle to prove it was present in the service environment. The “inability to obtain appropriate clinical management” factor (9(3)) is vague. It does not define “appropriate” or “inability” - is it an objective inability (no dermatologist available) or a subjective inability (claimant chose not to attend)? The factor likely requires a systemic failure of access, not personal choice. Note 2 under factor 9(1) warns that “cross-sensitisation may occur between allergens.” This could allow a claim where the actual allergen was not present but a chemically similar one was. But the decision-maker must still identify the cross-reactive substance and connect it to the service exposure, which may require expert evidence. Section 10(2) restricts factors 9(2) and 9(3) to “material contribution to, or aggravation of” allergic contact dermatitis where the condition was suffered or contracted before or during (but did not arise out of) relevant service. This means that if the dermatitis started before service, the claim must show service-related aggravation to a material degree, not just any worsening. The factor does not apply if the condition arose out of service. Claimants with pre-existing dermatitis need to distinguish between aggravation and natural progression. Finally, the note under section 8 states that the Repatriation Medical Authority is of the view that sound medical-scientific evidence exists. This is a statement of opinion, not a determination of fact in any particular case. A claimant cannot rely on this note alone; they must still prove the factors.

For a claimant seeking to have allergic contact dermatitis accepted as service-related, compliance means gathering evidence that satisfies at least one factor in section 9 and then establishing that the factor relates to relevant service. Step one is obtaining a medical diagnosis that meets the definition in section 7(2). The diagnosis should be made by a dermatologist or other specialist using patch testing for potential allergens. The diagnosis must explicitly exclude atopic dermatitis, irritant contact dermatitis, and the other exclusions. The medical report should state that the dermatitis is allergic contact dermatitis and identify the specific allergen(s) if possible. Step two is documenting exposure history. For factor 9(1), the claimant must show that the affected area of skin was exposed to the identified allergen within the two weeks before the first appearance of symptoms. This requires a timeline of potential contacts: uniforms, boots, gloves, creams, fuels, airborne chemicals during service. Service records, maintenance logs, or witness statements may help. For factor 9(1A), the claimant must show two distinct exposures: an earlier exposure without symptoms (sensitising exposure) and a subsequent exposure to the same allergen within the two weeks before onset. Evidence of the earlier exposure may be based on service activities even if no rash occurred at that time. For factor 9(2) (worsening), the claimant must show that an existing allergic contact dermatitis worsened due to allergen exposure within two weeks before the worsening, and that the worsening is material (more than trivial). For factor 9(3) (inability to obtain appropriate clinical management), the claimant must demonstrate that they could not access reasonable medical treatment for the dermatitis. This might involve evidence of remote posting, lack of dermatology services, or refusal of treatment by Defence Health Services. That factor does not require a temporal window but must be related to service.

Step three is linking the factor to relevant service. The claimant must show that the allergen exposure occurred during qualifying service (operational, peacekeeping, etc.) or, for aggravation claims, that the inability to obtain treatment occurred during service. This may involve connecting the allergen to a specific service location, activity, or piece of equipment. For example, nickel exposure from uniform buttons during service in a tropical environment, or chromium from cement on a construction deployment.

For decision-makers complying with this instrument, the process involves: verifying the diagnosis, confirming the condition falls within the definition, checking each claimed factor against the evidence, and ensuring the temporal requirements are met. If the claimant satisfies any factor and the factor relates to relevant service, the decision-maker must find that a reasonable hypothesis exists, unless there is proof beyond reasonable doubt to the contrary. Decision-makers must also consider cross-sensitisation if raised, and must apply section 11 if the factor refers to another disease. They should keep records of the reasoning.

For legal practitioners, compliance means framing the claim using the precise language of the factor. Avoid using “contact dermatitis” without specifying allergic aetiology. Use the definition from subsection 7(2). For the sensitising exposure factor, explicitly state the earlier exposure and the later re-exposure, both evidenced. Consider commissioning a report from a toxicologist or industrial hygienist if the allergen is uncommon. Stay informed of any further amendments; the instrument may be updated again if the Authority changes its view on medical science. The compilation date of 19 September 2022 is already over two years old; check the Federal Register of Legislation for current version.